Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 11,176 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Multiple Myeloma
Interventions: 64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT; Drug · Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions: TN-401; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Follicular Lymphoma
Interventions: Lisocabtagene maraleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2044
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Vascular Death, Myocardial Infarction, Stroke, Cardiac Surgery
Interventions: Not listed
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15,989 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more

Conditions: Acute Heart Failure With Reduced Ejection Fraction
Interventions: APD418, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more

Conditions: PARKINSON DISEASE (Disorder)
Interventions: VIM0423, VIM0423 Placebo; Drug
Lead sponsor: Vima Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 29
States / cities: Scottsdale, Arizona • Murrieta, California • Stamford, Connecticut + 25 more

Conditions: HIV-1-infection, HIV Disease Progression, Inflammation, HIV
Interventions: Venipuncture, Targeted physical medical exam, Urine pregnancy test, Anoscopy, Esophagogastroduodenoscopy (EGD); Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent
Interventions: SOC+BSB-2002; Drug
Lead sponsor: BlueSphere Bio, Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Educational Intervention, Minorities
Interventions: Educational Intervention; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream, TCS; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 5,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Dementia, Alzheimer Disease, Caregiver Burnout, Family Members
Interventions: STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias); Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Temozolomide; Biological · Drug
Lead sponsor: Dwight Owen; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Hypercholesterolemia
Interventions: AZD8233; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Interventions: NST-628; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
Interventions: Multidisciplinary Prehabilitation Program; Behavioral
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Digital Health Companion (mobile App); Behavioral
Lead sponsor: WV Health Right, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Multiple Myeloma
Interventions: daratumumab, carfilzomib, lenalidomide, dexamethasone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions: Tovorafenib; Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 39 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Parkinson's Disease
Interventions: Standard of Care; Other
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more

Conditions: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Tampa, Florida + 5 more

Search by objective public record fields.

64Cu-LLP2A for Imaging Multiple Myeloma

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

Patient Navigator PRE-ACT Educational Intervention to Promote Decision Making Among Minorities

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Assessing Acceptability, Cost, and Efficacy of STELLA-Support Via Technology

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

A Study of NST-628 in Recurrent Grade 4 Glioma

Prehabilitation in High-risk Oncologic Surgery

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations